Oral weight-loss tablets do not cannibalize injectables—they unlock an entirely new patient population.
By bypassing needle anxiety and rigid clinical administrative bounds, daily metabolic tablets capture massive, previously untreated consumer pools.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Massive early sales and prescription volumes of the oral tablet demonstrate its power to quickly capture an underserved, massive consumer segment without eroding injectable revenues.
Expanding regulatory approval of oral blockbusters to international regions ensures access to large, underserved patient groups who prioritize convenience.
The rapid adoption of the oral tablet form is driven almost entirely by patient populations who had never previously utilized injectable alternatives.